Literature DB >> 18402240

[Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension].

G H H Müller-Schwefe1, M A Uberall.   

Abstract

BACKGROUND: Chronic back pain is mainly caused by painful tension in the back muscles. Thus, analgesics with muscle tone decreasing effects that apparently normalize increased muscle tonus through specific modes of action without disturbing normal muscular movement are an important therapeutic option. Flupirtine retard (Katadolon S long) has provided such an option since 2006.
OBJECTIVES: To impartially evaluate the muscle tonus normalizing effects of flupirtine retard by applying specific, objective test methods in patients with chronic musculoskeletal pain under routine practice conditions.
METHODS: Prospective standardized evaluation of a treatment with flupirtine retard in 30 patients with continuous chronic, therapy refractory back pain. Measurement of general pain intensity, pain pressure threshold and pain pressure tolerance for trigger-point related pain and muscle tension in the affected back muscles before and during flupirtine retard treatment were performed in a standardized manner.
RESULTS: In comparison to the reproducible, constant initial values, the two-week treatment with flupirtine retard led to a significant improvement in all measured muscle-specific indicators: pain pressure threshold (+48%), pain pressure tolerance (+27%) and depth of penetration in the muscle (+18%) (all values p < 0.001). These were also correlated with a clinically observable and statistically significant pain relief from an initial level of 7.0 +/- 1.3 to 3.0 +/- 1.4.
CONCLUSION: Flupirtine retard was shown to be a useful, effective and very tolerable therapeutic option for patients with chronic back pain. The improvement of muscle disturbances which are responsible for the pain in addition to pain relief was shown firstly by objective measure methods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18402240

Source DB:  PubMed          Journal:  MMW Fortschr Med        ISSN: 1438-3276


  5 in total

1.  Role of flupirtine in the treatment of pain - chemistry and its effects.

Authors:  Rikki Singal; Parveen Gupta; Nidhi Jain; Samita Gupta
Journal:  Maedica (Buchar)       Date:  2012-06

Review 2.  Flupirtine in pain management: pharmacological properties and clinical use.

Authors:  Jacques Devulder
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

3.  Pressure algometry and enzyme-linked immunosorbent assay of natural antibodies in the evaluation of pain syndrome.

Authors:  A I Levashova; O Yu Artiushkova; V S Morozova; S N Petrochenko; M A Myagkova; I A Moseikin; L F Panchenko
Journal:  Dokl Biochem Biophys       Date:  2016-03-31       Impact factor: 0.788

Review 4.  [Chronic pain management].

Authors:  D Rothstein; M Zenz
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

5.  Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting.

Authors:  Nora Anderson; Juergen Borlak
Journal:  PLoS One       Date:  2011-10-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.